Although advances in diagnosis and treatment have substantially improved outcomes for patients with early-stage breast cancer, several important unmet clinical needs remain. Conventional risk stratification based on clinicopathological characteristics lacks sufficient precision to accurately identify patients at genuine risk of recurrence, resulting in undertreatment of some high-risk patients and overtreatment of others. During neoadjuvant therapy, current assessment methods are also unable to detect treatment response at the molecular level early enough to guide timely therapeutic adjustments.

As one of China's premier academic meetings in genitourinary oncology, the Pujiang Prostate Cancer Conference continues to serve as an important platform for integrating international advances with domestic clinical practice. This year's meeting featured a dedicated multidisciplinary session, bringing together leading Chinese experts to discuss emerging directions in prostate cancer management.

The Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026. Organized by the Shanghai Anti-Cancer Association and its Genitourinary Oncology Committee, and hosted by Fudan University Shanghai Cancer Center, the meeting focused on major clinical issues including salvage surgery following prostate cancer recurrence and the integration of multiple local treatment modalities.

The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The conference featured in-depth discussions on key topics including early prostate cancer screening and precision diagnosis, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care throughout the disease course.

The 2026 Pujiang Prostate Cancer Conference was successfully held in Shanghai under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration," with the goal of advancing standardized prostate cancer care and promoting innovation in key surgical techniques in China.

The 2026 Pujiang Prostate Cancer Conference was successfully held in Shanghai, bringing together leading experts to discuss the latest advances and clinical experience in prostate cancer management, further promoting standardized care and technological innovation in China.

The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The meeting brought together leading experts in uro-oncology from across China to showcase advances in standardized prostate cancer management and cutting-edge research.

At the 2026 ASCO Annual Meeting, Professor Claudio Vernieri from the Fondazione IRCCS Istituto Nazionale dei Tumori (Italy) presented the key findings of the PALMARES-2 study. Among patients with HR+/HER2− metastatic breast cancer, only about 20% continued first-line endocrine therapy (ET) plus a CDK4/6 inhibitor beyond first progression, achieving a median real-world progression-free survival (rwPFS) of 10.5 months and a median real-world overall survival (rwOS) of 71.3 months. The study also suggested that adding local treatment—particularly radiotherapy—was associated with improved outcomes.